The global antibody drug conjugates market size was USD 10.30 billion in 2023, estimated at USD 11.43 billion in 2024 and is anticipated to reach around USD 31.96 billion by 2034, expanding at a CAGR of 10.83% from 2025 to 2034. The antibody drug conjugates market is gaining strong momentum as innovative, targeted cancer therapies see increased adoption.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
7.1. Antibody Drug Conjugates Market, by Product
7.1.1. Kadcyla
7.1.1.1. Market Revenue and Forecast
7.1.2. Enhertu
7.1.2.1. Market Revenue and Forecast
7.1.3. Adcetris
7.1.3.1. Market Revenue and Forecast
7.1.4. Polivy
7.1.4.1. Market Revenue and Forecast
7.1.5. Trodelvy
7.1.5.1. Market Revenue and Forecast
7.1.6. Padcev
7.1.6.1. Market Revenue and Forecast
7.1.7. Besponsa
7.1.7.1. Market Revenue and Forecast
7.1.8. Elahere
7.1.8.1. Market Revenue and Forecast
7.1.9. Zylonta
7.1.9.1. Market Revenue and Forecast
7.1.10. Mylotarg
7.1.10.1. Market Revenue and Forecast
7.1.11. Tivdak
7.1.11.1. Market Revenue and Forecast
7.1.12. Others
7.1.12.1. Market Revenue and Forecast
8.1. Antibody Drug Conjugates Market, by Antigen Target
8.1.1. HER2 Receptor
8.1.1.1. Market Revenue and Forecast
8.1.2. CD22
8.1.2.1. Market Revenue and Forecast
8.1.3. CD30
8.1.3.1. Market Revenue and Forecast
8.1.4. Trop-2
8.1.4.1. Market Revenue and Forecast
8.1.5. CD79B
8.1.5.1. Market Revenue and Forecast
8.1.6. CD19
8.1.6.1. Market Revenue and Forecast
8.1.7. CD33
8.1.7.1. Market Revenue and Forecast
8.1.8. Nectin-4
8.1.8.1. Market Revenue and Forecast
8.1.9. Tissue Factor
8.1.9.1. Market Revenue and Forecast
8.1.10. Others
8.1.10.1. Market Revenue and Forecast
9.1. Antibody Drug Conjugates Market, by Antibody Generation
9.1.1. First Generation
9.1.1.1. Market Revenue and Forecast
9.1.2. Second Generation
9.1.2.1. Market Revenue and Forecast
9.1.3. Third Generation
9.1.3.1. Market Revenue and Forecast
9.1.4. Fourth Generation
9.1.4.1. Market Revenue and Forecast
10.1. Antibody Drug Conjugates Market, by Linker Type
10.1.1. Cleavable Linkers
10.1.1.1. Market Revenue and Forecast
10.1.2. Non-Cleavable Linkers
10.1.2.1. Market Revenue and Forecast
10.1.3. Linker-less ADCs
10.1.3.1. Market Revenue and Forecast
11.1. Antibody Drug Conjugates Market, by Payload Type
11.1.1. Monomethyl Auristatin E (MMAE)
11.1.1.1. Market Revenue and Forecast
11.1.2. Calicheamicin
11.1.2.1. Market Revenue and Forecast
11.1.3. Maytansinoids
11.1.3.1. Market Revenue and Forecast
11.1.4. Duocarmycins
11.1.4.1. Market Revenue and Forecast
11.1.5. PBD Dimers
11.1.5.1. Market Revenue and Forecast
11.1.6. Others
11.1.6.1. Market Revenue and Forecast
12.1. Antibody Drug Conjugates Market, by Linker Technology
12.1.1. VC Linker
12.1.1.1. Market Revenue and Forecast
12.1.2. Hydrazone Linker
12.1.2.1. Market Revenue and Forecast
12.1.3. Valine-Alanine Linker
12.1.3.1. Market Revenue and Forecast
12.1.4. Sulfo-SPDB Linker
12.1.4.1. Market Revenue and Forecast
12.1.5. Others
12.1.5.1. Market Revenue and Forecast
13.1. Antibody Drug Conjugates Market, by Application
13.1.1. Breast Cancer
13.1.1.1. Market Revenue and Forecast
13.1.2. Blood Cancers
13.1.2.1. Market Revenue and Forecast
13.1.3. Ovarian Cancer
13.1.3.1. Market Revenue and Forecast
13.1.4. Lung Cancer
13.1.4.1. Market Revenue and Forecast
13.1.5. Brain Tumors
13.1.5.1. Market Revenue and Forecast
13.1.6. Cervical Cancer
13.1.6.1. Market Revenue and Forecast
13.1.7. Other Solid Tumors
13.1.7.1. Market Revenue and Forecast
14.1. Antibody Drug Conjugates Market, by End User
14.1.1. Hospitals & Clinics
14.1.1.1. Market Revenue and Forecast
14.1.2. Specialty Cancer Centers
14.1.2.1. Market Revenue and Forecast
14.1.3. Research & Academic Institutions
14.1.3.1. Market Revenue and Forecast
14.1.4. Contract Research Organizations (CROs)
14.1.4.1. Market Revenue and Forecast
14.1.5. Pharmaceutical & Biotech Companies
14.1.5.1. Market Revenue and Forecast
14.1.6. Others
14.1.6.1. Market Revenue and Forecast
15.1. Antibody Drug Conjugates Market, by Distribution Channel
15.1.1. Direct Sales
151.1.1. Market Revenue and Forecast
15.1.2. Third-Party Distributors
15.1.2.1. Market Revenue and Forecast
15.1.3. Online Platforms
15.1.3.1. Market Revenue and Forecast
15.1.4. Others
15.1.4.1. Market Revenue and Forecast
16.1. North America
16.1.1. Market Revenue and Forecast, by Product
16.1.2. Market Revenue and Forecast, by Antigen Target
16.1.3. Market Revenue and Forecast, by Antibody Generation
16.1.4. Market Revenue and Forecast, by Linker Type
16.1.5. Market Revenue and Forecast, by Payload Type
16.1.6. Market Revenue and Forecast, by Linker Technology
16.1.7. Market Revenue and Forecast, by Application
16.1.8. Market Revenue and Forecast, by End User
16.1.9. Market Revenue and Forecast, by Distribution Channel
16.1.9. U.S.
16.1.9.1. Market Revenue and Forecast, by Product
16.1.9.2. Market Revenue and Forecast, by Antigen Target
16.1.9.3. Market Revenue and Forecast, by Antibody Generation
16.1.9.4. Market Revenue and Forecast, by Linker Type
16.1.9.5. Market Revenue and Forecast, by Payload Type
16.1.9.6. Market Revenue and Forecast, by Linker Technology
16.1.9.7. Market Revenue and Forecast, by Application
16.1.9.8. Market Revenue and Forecast, by End User
16.1.9.9. Market Revenue and Forecast, by Distribution Channel
16.1.10. Rest of North America
16.1.10.1. Market Revenue and Forecast, by Product
16.1.10.2. Market Revenue and Forecast, by Antigen Target
16.1.10.3. Market Revenue and Forecast, by Antibody Generation
16.1.10.4. Market Revenue and Forecast, by Linker Type
16.1.10.5. Market Revenue and Forecast, by Payload Type
16.1.10.6. Market Revenue and Forecast, by Linker Technology
16.1.10.7. Market Revenue and Forecast, by Application
16.1.10.8. Market Revenue and Forecast, by End User
16.1.10.9. Market Revenue and Forecast, by Distribution Channel
16.2. Europe
16.2.1. Market Revenue and Forecast, by Product
16.2.2. Market Revenue and Forecast, by Antigen Target
16.2.3. Market Revenue and Forecast, by Antibody Generation
16.2.4. Market Revenue and Forecast, by Linker Type
16.2.5. Market Revenue and Forecast, by Payload Type
16.2.6. Market Revenue and Forecast, by Linker Technology
16.2.7. Market Revenue and Forecast, by Application
16.2.8. Market Revenue and Forecast, by End User
16.2.9. Market Revenue and Forecast, by Distribution Channel
15.2.9. UK
16.2.9.1. Market Revenue and Forecast, by Product
16.2.9.2. Market Revenue and Forecast, by Antigen Target
16.2.9.3. Market Revenue and Forecast, by Antibody Generation
16.2.9.4. Market Revenue and Forecast, by Linker Type
16.2.9.5. Market Revenue and Forecast, by Payload Type
16.2.9.6. Market Revenue and Forecast, by Linker Technology
16.2.9.7. Market Revenue and Forecast, by Application
16.2.9.8. Market Revenue and Forecast, by End User
16.2.9.9. Market Revenue and Forecast, by Distribution Channel
16.2.10. Germany
16.2.10.1. Market Revenue and Forecast, by Product
16.2.10.2. Market Revenue and Forecast, by Antigen Target
16.2.10.3. Market Revenue and Forecast, by Antibody Generation
16.2.10.4. Market Revenue and Forecast, by Linker Type
16.2.10.5. Market Revenue and Forecast, by Payload Type
16.2.10.6. Market Revenue and Forecast, by Linker Technology
16.2.10.7. Market Revenue and Forecast, by Application
16.2.10.8. Market Revenue and Forecast, by End User
16.2.10.9. Market Revenue and Forecast, by Distribution Channel
16.2.11. France
16.2.11.1. Market Revenue and Forecast, by Product
16.2.11.2. Market Revenue and Forecast, by Antigen Target
16.2.11.3. Market Revenue and Forecast, by Antibody Generation
16.2.11.4. Market Revenue and Forecast, by Linker Type
16.2.11.5. Market Revenue and Forecast, by Payload Type
16.2.11.6. Market Revenue and Forecast, by Linker Technology
16.2.11.7. Market Revenue and Forecast, by Application
16.2.11.8. Market Revenue and Forecast, by End User
16.2.11.9. Market Revenue and Forecast, by Distribution Channel
16.2.12. Rest of Europe
16.2.12.1. Market Revenue and Forecast, by Product
16.2.12.2. Market Revenue and Forecast, by Antigen Target
16.2.12.3. Market Revenue and Forecast, by Antibody Generation
16.2.12.4. Market Revenue and Forecast, by Linker Type
16.2.12.5. Market Revenue and Forecast, by Payload Type
16.2.12.6. Market Revenue and Forecast, by Linker Technology
16.2.12.7. Market Revenue and Forecast, by Application
16.2.12.8. Market Revenue and Forecast, by End User
16.2.12.9. Market Revenue and Forecast, by Distribution Channel
16.3. APAC
16.3.1. Market Revenue and Forecast, by Product
16.3.2. Market Revenue and Forecast, by Antigen Target
16.3.3. Market Revenue and Forecast, by Antibody Generation
16.3.4. Market Revenue and Forecast, by Linker Type
16.3.5. Market Revenue and Forecast, by Payload Type
16.3.6. Market Revenue and Forecast, by Linker Technology
16.3.7. Market Revenue and Forecast, by Application
16.3.8. Market Revenue and Forecast, by End User
16.3.9. Market Revenue and Forecast, by Distribution Channel
16.3.9. India
16.3.9.1. Market Revenue and Forecast, by Product
16.3.9.2. Market Revenue and Forecast, by Antigen Target
16.3.9.3. Market Revenue and Forecast, by Antibody Generation
16.3.9.4. Market Revenue and Forecast, by Linker Type
16.3.9.5. Market Revenue and Forecast, by Payload Type
16.3.9.6. Market Revenue and Forecast, by Linker Technology
16.3.9.7. Market Revenue and Forecast, by Application
16.3.9.8. Market Revenue and Forecast, by End User
16.3.9.9. Market Revenue and Forecast, by Distribution Channel
16.3.10. China
16.3.10.1. Market Revenue and Forecast, by Product
16.3.10.2. Market Revenue and Forecast, by Antigen Target
16.3.10.3. Market Revenue and Forecast, by Antibody Generation
16.3.10.4. Market Revenue and Forecast, by Linker Type
16.3.10.5. Market Revenue and Forecast, by Payload Type
16.3.10.6. Market Revenue and Forecast, by Linker Technology
16.3.10.7. Market Revenue and Forecast, by Application
16.3.10.8. Market Revenue and Forecast, by End User
16.3.10.9. Market Revenue and Forecast, by Distribution Channel
16.3.11. Japan
16.3.11.1. Market Revenue and Forecast, by Product
16.3.11.2. Market Revenue and Forecast, by Antigen Target
16.3.11.3. Market Revenue and Forecast, by Antibody Generation
16.3.11.4. Market Revenue and Forecast, by Linker Type
16.3.11.5. Market Revenue and Forecast, by Payload Type
16.3.11.6. Market Revenue and Forecast, by Linker Technology
16.3.11.7. Market Revenue and Forecast, by Application
16.3.11.8. Market Revenue and Forecast, by End User
16.3.11.9. Market Revenue and Forecast, by Distribution Channel
16.3.12. Rest of APAC
16.3.12.1. Market Revenue and Forecast, by Product
16.3.12.2. Market Revenue and Forecast, by Antigen Target
16.3.12.3. Market Revenue and Forecast, by Antibody Generation
16.3.12.4. Market Revenue and Forecast, by Linker Type
16.3.12.5. Market Revenue and Forecast, by Payload Type
16.3.12.6. Market Revenue and Forecast, by Linker Technology
16.3.12.7. Market Revenue and Forecast, by Application
16.3.12.8. Market Revenue and Forecast, by End User
16.3.12.9. Market Revenue and Forecast, by Distribution Channel
16.4. MEA
16.4.1. Market Revenue and Forecast, by Product
16.4.2. Market Revenue and Forecast, by Antigen Target
16.4.3. Market Revenue and Forecast, by Antibody Generation
16.4.4. Market Revenue and Forecast, by Linker Type
16.4.5. Market Revenue and Forecast, by Payload Type
16.4.6. Market Revenue and Forecast, by Linker Technology
16.4.7. Market Revenue and Forecast, by Application
16.4.8. Market Revenue and Forecast, by End User
16.4.9. Market Revenue and Forecast, by Distribution Channel
16.4.9. GCC
16.4.9.1. Market Revenue and Forecast, by Product
16.4.9.2. Market Revenue and Forecast, by Antigen Target
16.4.9.3. Market Revenue and Forecast, by Antibody Generation
16.4.9.4. Market Revenue and Forecast, by Linker Type
16.4.9.5. Market Revenue and Forecast, by Payload Type
16.4.9.6. Market Revenue and Forecast, by Linker Technology
16.4.9.7. Market Revenue and Forecast, by Application
16.4.9.8. Market Revenue and Forecast, by End User
16.4.9.9. Market Revenue and Forecast, by Distribution Channel
16.4.10. North Africa
16.4.10.1. Market Revenue and Forecast, by Product
16.4.10.2. Market Revenue and Forecast, by Antigen Target
16.4.10.3. Market Revenue and Forecast, by Antibody Generation
16.4.10.4. Market Revenue and Forecast, by Linker Type
16.4.10.5. Market Revenue and Forecast, by Payload Type
16.4.10.6. Market Revenue and Forecast, by Linker Technology
16.4.10.7. Market Revenue and Forecast, by Application
16.4.10.8. Market Revenue and Forecast, by End User
16.4.10.9. Market Revenue and Forecast, by Distribution Channel
16.4.11. South Africa
16.4.11.1. Market Revenue and Forecast, by Product
16.4.11.2. Market Revenue and Forecast, by Antigen Target
16.4.11.3. Market Revenue and Forecast, by Antibody Generation
16.4.11.4. Market Revenue and Forecast, by Linker Type
16.4.11.5. Market Revenue and Forecast, by Payload Type
16.4.11.6. Market Revenue and Forecast, by Linker Technology
16.4.11.7. Market Revenue and Forecast, by Application
16.4.11.8. Market Revenue and Forecast, by End User
16.4.11.9. Market Revenue and Forecast, by Distribution Channel
16.4.12. Rest of MEA
16.4.12.1. Market Revenue and Forecast, by Product
16.4.12.2. Market Revenue and Forecast, by Antigen Target
16.4.12.3. Market Revenue and Forecast, by Antibody Generation
16.4.12.4. Market Revenue and Forecast, by Linker Type
16.4.12.5. Market Revenue and Forecast, by Payload Type
16.4.12.6. Market Revenue and Forecast, by Linker Technology
16.4.12.7. Market Revenue and Forecast, by Application
16.4.12.8. Market Revenue and Forecast, by End User
16.4.12.9. Market Revenue and Forecast, by Distribution Channel
16.5. Latin America
16.5.1. Market Revenue and Forecast, by Product
16.5.2. Market Revenue and Forecast, by Antigen Target
16.5.3. Market Revenue and Forecast, by Antibody Generation
16.5.4. Market Revenue and Forecast, by Linker Type
16.5.5. Market Revenue and Forecast, by Payload Type
16.5.6. Market Revenue and Forecast, by Linker Technology
16.5.7. Market Revenue and Forecast, by Application
16.5.8. Market Revenue and Forecast, by End User
16.5.9. Market Revenue and Forecast, by Distribution Channel
16.5.9. Brazil
16.5.9.1. Market Revenue and Forecast, by Product
16.5.9.2. Market Revenue and Forecast, by Antigen Target
16.5.9.3. Market Revenue and Forecast, by Antibody Generation
16.5.9.4. Market Revenue and Forecast, by Linker Type
16.5.9.5. Market Revenue and Forecast, by Payload Type
16.5.9.6. Market Revenue and Forecast, by Linker Technology
16.5.9.7. Market Revenue and Forecast, by Application
16.5.9.8. Market Revenue and Forecast, by End User
16.5.9.9. Market Revenue and Forecast, by Distribution Channel
16.5.10. Rest of LATAM
16.5.10.1. Market Revenue and Forecast, by Product
16.5.10.2. Market Revenue and Forecast, by Antigen Target
16.5.10.3. Market Revenue and Forecast, by Antibody Generation
16.5.10.4. Market Revenue and Forecast, by Linker Type
16.5.10.5. Market Revenue and Forecast, by Payload Type
16.5.10.6. Market Revenue and Forecast, by Linker Technology
16.5.10.7. Market Revenue and Forecast, by Application
16.5.10.8. Market Revenue and Forecast, by End User
16.5.10.9. Market Revenue and Forecast, by Distribution Channel
17.1. Takeda Pharmaceutical Company Limited
17.1.1. Company Overview
17.1.2. Product Offerings
17.1.3. Financial Performance
17.1.4. Recent Initiatives
17.2. Pfizer Inc
17.2.1. Company Overview
17.2.2. Product Offerings
17.2.3. Financial Performance
17.2.4. Recent Initiatives
17.3. GlaxoSmithKline Plc
17.3.1. Company Overview
17.3.2. Product Offerings
17.3.3. Financial Performance
17.3.4. Recent Initiatives
17.4. AstraZeneca
17.4.1. Company Overview
17.4.2. Product Offerings
17.4.3. Financial Performance
17.4.4. Recent Initiatives
17.5. Seagen Inc
17.5.1. Company Overview
17.5.2. Product Offerings
17.5.3. Financial Performance
17.5.4. Recent Initiatives
17.6. ADC Therapeutics
17.6.1. Company Overview
17.6.2. Product Offerings
17.6.3. Financial Performance
17.6.4. Recent Initiatives
17.7. Gilead Sciences Inc
17.7.1. Company Overview
17.7.2. Product Offerings
17.7.3. Financial Performance
17.7.4. Recent Initiatives
17.8. F. Hoffmann-La Roche Ltd
17.8.1. Company Overview
17.8.2. Product Offerings
17.8.3. Financial Performance
17.8.4. Recent Initiatives
18.7. Primary Research
18.7. Secondary Research
18.7. Assumptions
19.1. About Us
19.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description